That when a new drug is developed for pain relief, a "significant" reduction is 20% using the VAS score. The study just presented describes success as a 50% reduction.
Despite that, the success rate is better for Scrambler.
So more than 50% with neuropathic pain got more than 50% pain relief under less than ideal conditions.
I can see you are rolling on the floor laughing; laughing for joy for all those neuropathic pain sufferers who have a promising treatment confirmed with this new study.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.